Necrotizing Myopathy (NM)Symptoms, Doctors, Treatments, Advances & More
Learn About Necrotizing Myopathy (NM)
Johns Hopkins Bayview Medical Center
Andrew Mammen is a Neuromusculoskeletal Medicine specialist and a Neurologist practicing medicine in Baltimore, Maryland. Dr. Mammen is rated as an Elite provider by MediFind in the treatment of Necrotizing Myopathy (NM). He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Myositis, Polymyositis, Dermatomyositis, and Necrotizing Myopathy (NM). Dr. Mammen is board certified in American Board Of Psychiatry And Neurology.
MN - Neuro
Margherita Milone is a Neurologist practicing medicine in Rochester, Minnesota. Dr. Milone is rated as an Elite provider by MediFind in the treatment of Necrotizing Myopathy (NM). She is also highly rated in 36 other conditions, according to our data. Her clinical expertise encompasses Necrotizing Myopathy (NM), Nemaline Myopathy, Progressive External Ophthalmoplegia, and Tubular Aggregate Myopathy. Dr. Milone is board certified in MN State Medical License 2003-2023.
Texas Health Family Care
Charles Kwaw is a primary care provider, practicing in Internal Medicine and Pediatrics in Fort Worth, Texas. Dr. Kwaw is rated as an Advanced provider by MediFind in the treatment of Necrotizing Myopathy (NM). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Familial Combined Hyperlipidemia, Xanthoma, Cirrhosis, and Ureteroscopy.
Summary: This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy. The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated ...
Summary: This is a randomized, placebo-controlled, double blinded phase 2 exploratory clinical trial of intravenously administered pooled human immunoglobulin (IVIG) in anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune mediated necrotizing myopathy (IMNM). Planned enrollment is 12 individuals with active anti-HMGCR IMNM meeting inclusion and exclusion criteria. Assuming 20% drop-out, the investi...